Afya reaffirmed its 2026 revenue guidance of R$3.95 billion to R$4.1 billion.
The company maintained its 2026 adjusted EBITDA guidance of R$1.7 billion to R$1.8 billion.
Afya expects 2026 capex between R$340 million and R$380 million.
Overview
The medical education group's Q2 revenue excluding acquisitions grew 5.4% year over year.
Adjusted EBITDA for Q2 rose 1.4% year over year, while the margin declined due to higher expenses and revenue mix.
The company returned R$448 million to shareholders in 1H26 via dividends and share repurchases.
Result drivers
Medical schools growth — Revenue growth was mainly driven by Medical Schools, supported by higher net average ticket and expansion of the student base.
— Health Sciences undergraduate programs contributed to revenue growth through an in the student base.
AFYA•
